IP Library › Granted Patent US 7,196,205
Granted Patent B2
US 7,196,205 · App. 11/091,836 · Granted Mar 27, 2007

Synthesis of UDP-glucose:

Assignees: The Regents of the University of Michigan; Genzyme Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,196,205
App. No.
11/091,836
Granted
Mar 27, 2007
Kind
B2
Abstract

Disclosed is a novel enantiomeric synthesis ceramide-like inhibitors of UDP-glucose: N-acylsphingosine glucosyltransferase. Also disclosed are novel intermediates formed during the synthesis.

Claims (18)

1. A compound represented by the following structural formula:

or a physiologically acceptable salt thereof.

2. A compound represented by the following structural formula:

or a physiologically acceptable salt thereof.

3. The compound of claim 1 , wherein the compound has an enantiomeric excess of at least 10%.

4. The compound of claim 1 , wherein the compound has an enantiomeric excess of at least 25%.

5. The compound of claim 1 , wherein the compound has an enantiomeric excess of at least 50%.

6. The compound of claim 1 , wherein the compound has an enantiomeric excess of at least 75%.

7. The compound of claim 1 , wherein the compound has an enantiomeric excess of at least 90%.

8. The compound of claim 1 , wherein the compound has an enantiomeric excess of at least 95%.

9. The compound of claim 1 , wherein the compound has an enantiomeric excess of at least 99%.

10. The compound of claim 2 , wherein the compound has an enantiomeric excess of at least 10%.

11. The compound of claim 2 , wherein the compound has an enantiomeric excess of at least 25%.

12. The compound of claim 2 , wherein the compound has an enantiomeric excess of at least 50%.

13. The compound of claim 2 , wherein the compound has an enantiomeric excess of at least 75%.

14. The compound of claim 2 , wherein the compound has an enantiomeric excess of at least 90%.

15. The compound of claim 2 , wherein the compound has an enantiomeric excess of at least 95%.

16. The compound of claim 2 , wherein the compound has an enantiomeric excess of at least 99%.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2005
From: SIEGEL, CRAIG; NELSON, CAROL A.; HARRIS, DAVID J.; COPELAND, DIANE P.
To: GENZYME CORPORATION
Reel/Frame 016430/0852 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2005
From: SHAYMAN, JAMES A.
To: REGENTS OF THE UNIVERSITY OF MICHIGAN, THE
Reel/Frame 016430/0860 →
Continuity (4)
Continuation 1091682400 · Aug 12, 2004
Division 1019722700 · Jul 16, 2002
Provisional Application 6030581400 · Jul 16, 2001
Related Publication 20050222244A1 · Oct 6, 2005